The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
923
May 27, 1994
View Complete Issue         Table of Contents 2019 
Fluvastatin for Lowering Cholesterol
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fluvastatin for Lowering Cholesterol
May 27, 1994 (Issue: 923)
Fluvastatin (Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from previously available drugs in this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fluvastatin for Lowering Cholesterol
Article code: 923a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.